Aligos Therapeutics, Inc. Earnings Per Share (Basic)
Aligos Therapeutics, Inc. (ALGS) reported Earnings Per Share (Basic) of -$0.14 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Aligos Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.14.
- Aligos Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$2.21, a 143.16% decline year-over-year.
- Aligos Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$1.91.
- Aligos Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$3.04.
- Aligos Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$2.45.
- Aligos Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$20.94.
- Aligos Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$34.20.
- Aligos Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$2.25.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.14 10-Q · filed 2026-08-06 | -$2.36 10-Q · filed 2026-08-06 | -$4.27 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$7.31 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2026-03-31 | -$2.21 10-Q · filed 2026-05-07 | -$4.13 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$7.17 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$8.70 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-12-31 | -$1.91 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$4.95 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$6.49 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.45 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | -$3.04 10-Q · filed 2025-11-06 | -$4.58 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.44 10-Q · filed 2025-11-06 | -$9.77 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-06-30 | -$1.53 10-Q · filed 2026-08-06 | $2.90 10-Q · filed 2026-08-06 | -$6.58 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$9.48 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-03-31 | $5.12 10-Q · filed 2026-05-07 | -$5.32 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$8.35 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$7.83 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2024-12-31 | -$13.08 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$16.15 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$15.36 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$20.94 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | -$3.07 10-Q · filed 2025-11-06 | -$2.27 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$7.84 10-Q · filed 2025-11-06 | -$12.91 derived: net income ÷ weighted average shares · filed 2025-11-06 | ||||
| 2024-06-30 | $0.81 10-Q · filed 2025-08-06 | $0.03 10-Q · filed 2024-08-06 | -$4.77 10-Q · filed 2025-08-06 | -$0.19 10-Q · filed 2024-08-06 | -$9.85 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$15.69 derived: net income ÷ weighted average shares · filed 2025-11-06 | ||
| 2024-03-31 | -$5.58 10-Q · filed 2025-05-06 | -$0.22 10-Q · filed 2024-05-07 | -$11.09 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$18.57 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$7.08 derived: net income ÷ weighted average shares · filed 2025-11-06 | |||
| 2023-12-31 | -$5.50 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$13.49 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$3.88 derived: net income ÷ weighted average shares · filed 2025-03-10 | -$34.20 10-K · filed 2025-03-10 | -$1.36 10-K · filed 2024-03-12 | |||
| 2023-09-30 | -$10.37 10-Q · filed 2024-11-06 | -$0.41 10-Q · filed 2023-11-02 | -$1.64 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$34.59 10-Q · filed 2024-11-06 | -$1.38 10-Q · filed 2023-11-02 | -$2.50 derived: net income ÷ weighted average shares · filed 2024-11-06 | ||
| 2023-06-30 | -$0.43 10-Q · filed 2024-08-06 | -$0.97 10-Q · filed 2024-08-06 | -$1.48 derived: net income ÷ weighted average shares · filed 2024-08-06 | -$1.92 derived: net income ÷ weighted average shares · filed 2024-08-06 | ||||
| 2023-03-31 | -$0.53 10-Q · filed 2024-05-07 | -$1.05 derived: net income ÷ weighted average shares · filed 2024-05-07 | -$1.48 derived: net income ÷ weighted average shares · filed 2024-05-07 | -$1.95 derived: net income ÷ weighted average shares · filed 2024-05-07 | ||||
| 2022-12-31 | -$0.51 derived: net income ÷ weighted average shares · filed 2024-03-12 | -$0.95 derived: net income ÷ weighted average shares · filed 2024-03-12 | -$1.41 derived: net income ÷ weighted average shares · filed 2024-03-12 | -$2.25 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | -$0.44 10-Q · filed 2023-11-02 | -$0.90 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$1.74 10-Q · filed 2023-11-02 | |||||
| 2022-06-30 | -$0.47 10-Q · filed 2023-08-03 | -$1.30 10-Q · filed 2023-08-03 | ||||||
| 2022-03-31 | -$0.84 10-Q · filed 2023-05-04 | |||||||
| 2021-09-30 | -$0.78 10-Q · filed 2022-11-02 | -$2.31 10-Q · filed 2022-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |